The invention belongs to the technical field of physics, more precisely to measuring electrical signals.
An aspect of the invention is aimed to a device and a method using said device, for measuring and recording certain electrophysiological signals.
There is a great need for flexible, large-scale and high-density arrays with a wide electrophysiological recording bandwidth. Flexible, large-scale and high-density electrode arrays are state-of-the-art. However, those arrays do not provide high-fidelity recordings in the entire frequency bandwidth of electrophysiological signals.
Electrophysiological signals exist in a wide range of frequencies and amplitudes: from minute-long, high-amplitude signals such as cortical spreading depression to millisecond-long microvolt spikes. Recording the full range of electrophysiological signals with high-spatiotemporal resolution would be beneficial to unravel its relation and interactions and to ensure that no meaningful information is lost.
Most microelectrode arrays suffer from voltage drift and oscillations that affect its recording performance of infraslow signals, which frequency is below 0.1 Hz. This is so widely known, that most recording systems include high-pass filters to solve saturation issues that may arise due to baseline drift, at the cost of excluding potential physiological and pathological information from being recorded.
In the last years, there has been a particular resurgence of interest in fluctuations of brain activity at frequencies below 0.1 Hz, commonly referred to as very slow, ultraslow or infraslow activity (ISA). They are suggested to be indicative of brain states (e.g. sleep, anesthesia, coma, wakefulness) and were found to be correlated with resting-state networks in functional magnetic resonance imaging. They also may significantly contribute to the high variability observed in the time course of physiological signals.
There are some reported infraslow signals, such as cortical propagation waves called “cortical spreading depression (CSD)” that are only registered at very low frequencies and therefore it is very difficult to study them in a habitual way due to the impediment of the current electrodes. CSDs are defined as a wave of slow propagation of depolarization of neurons and astrocytes followed by a period of suppression of brain activity and are often triggered when there is a brain episode as in patients who have a vascular or traumatic brain stroke as well as in migraines and other brain pathologies. To monitor or detect them could improve the diagnosis but above all influence on therapeutic changes.
Full-band recordings including infralow frequencies have been traditionally performed with non-invasive techniques such as electroencephalography (EEG) and magnetoencephalography (MEG). However, their limited spatial resolution and averaged signal impose serious limitations; e.g. EEG alone has not yet been sufficient for non-invasive CSD detection. For these reason, invasive electrophysiological techniques are the most commonly used to record infraslow brainwaves.
The proper recording of ISA requires the use of direct-coupled amplifiers and extremely stable and low-impedance invasive electrodes. Traditionally, liquid-filled glass micropipettes are used, which allow only one or few-point measurements. For higher spatial resolution and mapping, non-polarizable silver/silver chloride (Ag/AgCl) electrodes could be used, which prevent charge accumulation at the interface and therefore voltage drift. However, due to the toxicity of silver, the use of such electrodes for human or chronic animal in vivo monitoring is not an option. This has fostered the search for alternative microelectrode materials with low impedance and drift although none has yet been found capable of offering comparable performance as Ag/AgCl electrodes. So, ISA recordings in humans are currently performed with platinum electrodes, which challenge CSD detection due to artifacts and transients. Importantly, baseline drift in the form of baseline oscillations in the infralow frequencies, hamper the determination of its “true” characteristics such as amplitude or waveform as any high-pass filter used to remove such effects will alter the signal shape.
Another intrinsic limitation of microelectrode technology is based on the relation between the microelectrode impedance and the input impedance of the recording equipment (Z′e and Z′a, respectively).
The recorded signal (Vin) is determined by the voltage divider formed by both impedances:
Eq. (1) implies that when Z′a, is not substantially larger than Z′e, the recorded signals will be attenuated and delayed with respect to Vsig. Even using high-input impedance amplifiers, for 50 μm diameter gold microelectrodes, an attenuation of more than 50% is expected. It is important to highlight that the Z′a»Z′e requirement to achieve a voltage gain equal to 1 is compromised when the electrode area is scaled down, due to the inverse relation between electrode impedance and its area leading to high-pass filtering of the recorded signals.
Therefore, miniaturization of electrode size to achieve higher spatial resolution causes intrinsic high-pass filtering of ISA due to the associated electrode impedance increase.
Invasive optical techniques such as calcium imaging are also used to monitor ISA, but still nowadays have serious challenges to resolve high-frequency activity for a large number of neurons24,25 and their intrinsic need of indicators limits the translation to the clinics. Therefore, a technique which allows for measuring large-scale, high-spatiotemporal resolution recordings including infraslow frequencies in a potentially fully implantable, nontoxic, clinical-scale system is still missing.
Alternatively to the commonly used microelectrode technology, recording electrophysiological signals with field-effect transistors (FET) offers several advantages including that they are less sensitive to environmental noise thanks to their intrinsic voltage-to-current amplification, and that they can be easily multiplexed26. Nonetheless, the difficulties to combine high gate capacitance and carrier mobility silicon FETs with flexible materials has historically hampered its use for in vivo recordings. Graphene solution-gated field-effect transistors (gSGFETs) have been proposed to potentially overcome most previous drawbacks. Graphene flexibility allows gSGFETs to be embedded in ultra-soft and flexible substrates without loss of performance, while its wide electrochemical window and biocompatibility allows direct contact with biological fluids and tissues and ensures a safe operation in in vivo conditions. In addition, the two-dimensional nature of graphene provides the highest surface-to-volume ratio possible, making graphene very sensitive to charges at its surface. Importantly, the frequency response of the transconductance of a gSGFET, is flat in a wide bandwidth including inflalow frequencies.
On the other hand, graphene based solution-gated field effect transistors (G-SgFETs) have been extensively investigated as potential biosensors for various analytes, like in WO2011004136A1 where it is disclosed a sensor for detecting the presence of at least one biological molecule and a method for the production of such a sensor which comprises a patterned graphene structure, at least two electric contacts arranged in contact with the patterned graphene structure for determining a conductivity; and at least one linker attached to at least a portion of the patterned graphene structure, wherein the at least one linker has a binding affinity for the at least one biological molecule.
The present invention, according to an aspect, addresses the need for flexible, large-scale and high-density arrays with a wide electrophysiological recording bandwidth. According to an aspect of the invention there is provided a graphene solution-gated field-effect transistor (gSGFETs) preferably an array of graphene solution-gated field-effect transistor (gSGFETs) which are able to record infraslow signals alongside with signals in the typical local field potential bandwidth. The graphene solution-gated field-effect transistor (gSGFETs) preferably are preferably placed on epicortical and intracortical positions.
The present invention may, according to an aspect, simultaneously overcomes the challenges remaining in the prior art by providing vastly increased baseline stability that arises from the electrochemical inertness of graphene, as also surpasses the signal attenuation due to the impedance divisor present in electrode recording systems by using a transistor as a recording element.
The graphene solution-gated field-effect transistor (gSGFETs) according to an aspect of the present invention is fabricated using flexible substrate to overcome the difficulty in conforming to the geometry of different biological structures, hence the graphene solution-gated field-effect transistor (gSGFETs) is preferably flexible. Also, when arranged in an array, said array is designed in an extensible manner such that transistors can be scaled up from micro to macro scale as needed while different kinds of electrical contacts, such as those that sit on the surface of (as oppose to penetrating) tissue.
Hence, the graphene transistor system for measuring electrophysiological signal of the invention encompasses a processing unit, and at least one graphene transistor (gSGFET) comprising graphene as channel material contacted by two terminals, to which a tunable voltage source at the drain and source terminals of the transistor (gSGFET) referred to the gate voltage, and at least one filter (a low-pass filter (LPF) with a gain of 104 configured to generate a low-pass filtered band with a frequency set between 0 Hz and 0.16 Hz or a band-pass filter (BPF) with a gain of 106 configured to generate a band-filtered band with a frequency comprised between 0.16 Hz and 10 kHz) configured to acquire and split the signal from the transistor into at least two frequency bands, low frequency band and high frequency band, are connected; being the first and second signals respectively amplified with a gain value.
The method and associated apparatus of the invention according to certain aspects of the invention may address the above-mentioned needs in the art by providing an amplification of the signals as also the capability to measure the transistor transfer curve at the site of recording. That allows both choosing the best operation point of the transistor and to apply a calibration methodology (current-to-voltage conversion of the recorded signal) that ensures a high-fidelity recording in a wide-bandwidth.
One of the main applications of aspects of the invention may be monitoring full-band brain signals; in either research or clinic implementations like in neurology. These same advantages exist for applications to other biological systems outside of the brain, such as heart, kidneys, stomach, cranial nerves, and other regions. The flexibility and versatility of graphene-transistor arrays allows several applications and deployments which range from subdural, epidural and intracortical devices to other placements in the brain, peripheral and cranial nerves, heart, blood vessels, spinal cord and other biological structures or non-invasive placement similar to an electroencephalogram.
To complement the description being made and in order to aid towards a better understanding of the characteristics of the invention, in accordance with a preferred example of practical embodiment thereof, a set of drawings is attached as an integral part of said description wherein, with illustrative and non-limiting character, the following has been represented:
A first aspect of the invention is aimed to a system for registering electrofysiological infraslow signals like cortical spreading depression (CSD) signals i.e. those with a frequency value below 0.1 Hz; the device comprising a processing unit associated or embedded in the very device, and at least one graphene transistor (gSGFET), preferably an array of graphene transistors, comprising graphene as channel material contacted by source and drain terminals, with a reference as gate terminal. Said graphene transistor is connected to at least a filter like a low pass filter (LPF). The recorded current signal is transformed into a voltage signal using the transistor transfer curve Ids-Vgs recorded to the start of the recordings).
In an alternative embodiment of the invention, at least one band pass filter (BPF) is arranged in either a sequential or a cascade arrangement along with the low pass filter (LPF). but both filters (LPF, BPF) being configured so that the respective cutting points have the same value.
An gSGFETS is a device in which graphene is used as channel material, contacted by two metal leads (source and drain terminals), and is immersed in an electrolyte solution where a reference electrode is used as gate terminal (
The device of the invention was compared to conventional high-pass filtered recordings, to do so the propagation of cortical spreading depression (CSD) events using a 4×4 epicortical gSGFET array was mapped and then compared with what is observed in conventional high-pass filtered recordings (
To further illustrate the potential of the device of the invention and taking advantage of the design versatility offered by this technology, a linear array of 15 gSGFETs spanning the entire depth of the cortex (
In a second aspect of the invention a method for recording infraslow brain signals, being infraslow signals those with a frequency value below 0.1 Hz is provided, Cortical spreading depression (CSD) was chosen to illustrate the capabilities of aspects of the invention to record in a wide bandwidth. Experimentally, two craniotomies were performed over the left hemisphere of isoflurane-anaesthetized Wistar rats: a larger craniotomy over the primary somatosensory cortex, where the epicortical probe was placed, and a smaller one in the frontal cortex, where 5 mM KCI was applied locally to induce CSD (
Number | Date | Country | Kind |
---|---|---|---|
P201831068 | Nov 2018 | ES | national |
This is a continuation application of co-pending international patent application PCT/ES2019/070728, filed Oct. 28, 2019 and designating the United States, which was published in Spanish as WO 2020/094898 A1, and claims priority to Spanish patent application P201831068, filed Nov. 6, 2018, all the subject matters of which are incorporated herein by this reference for all purposes.
Number | Date | Country | |
---|---|---|---|
Parent | PCT/ES2019/070728 | Oct 2019 | US |
Child | 17313469 | US |